AG
TCRT icon

Aperio Group’s Alaunos Therapeutics TCRT Stock Holding History

Aperio Group’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$104K Buy
274
+90
+49% +$35.8K ﹤0.01% 2378
2020
Q3 		$70K Sell
184
-190
-51% -$83.9K ﹤0.01% 2341
2020
Q2 		$184K Buy
374
+28
+8% +$12.5K ﹤0.01% 2193
2020
Q1 		$127K Buy
+346
New +$179K ﹤0.01% 2183
2019
Q3 		– Sell
-40
Closed -$35K – 2712
2019
Q2 		$35K Buy
+40
New +$27.5K ﹤0.01% 2605
2018
Q4 		– Sell
-79
Closed -$38K – 2335
2018
Q3 		$38K Buy
+79
New +$33.9K ﹤0.01% 2276

Other funds holding TCRT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Aperio Group's TCRT Position: Q4 2020 in Review

Aperio Group increased its Alaunos Therapeutics (TCRT) stake by 49% in Q4 2020, buying an estimated $35.8K and bringing the position to 274 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #2378.

Aperio Group first reported a position in TCRT in Q3 2018 and has held it in 6 quarters since. The position peaked at $184K in Q2 2020. 156 funds tracked by Wall St. Rank hold TCRT as of Q4 2020.

  • Aperio Group held 274 shares of Alaunos Therapeutics worth $104K as of Q4 2020.
  • Aperio Group bought 90 Alaunos Therapeutics shares in Q4 2020, an estimated $35.8K.
  • Alaunos Therapeutics made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2378 holding.
  • Aperio Group first reported a position in Alaunos Therapeutics in Q3 2018 and has held it in 6 quarters since.
  • Aperio Group's Alaunos Therapeutics position peaked at $184K in Q2 2020.
  • 156 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.